Jakafi and Cirrhosis alcoholic - a phase IV clinical study of FDA data
Cirrhosis alcoholic is reported only by a few people who take Jakafi.
The phase IV clinical study analyzes which people take Jakafi and have Cirrhosis alcoholic. It is created by eHealthMe based on reports of 46,732 people who have side effects while taking Jakafi from the FDA, and is updated regularly.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
46,732 people reported to have side effects when taking Jakafi.
Among them, 1 person (0.0%) has Cirrhosis alcoholic.
What is Jakafi?
Jakafi has active ingredients of ruxolitinib phosphate. It is often used in primary myelofibrosis. eHealthMe is studying from 40,564 Jakafi users for its effectiveness, alternative drugs and more.
What is Cirrhosis alcoholic?
Cirrhosis alcoholic (chronic disease of the liver marked by degeneration of cells, inflammation, and fibrous thickening of tissue caused by alcoholism) is found to be associated with 363 drugs and 162 conditions by eHealthMe.
Number of Jakafi and Cirrhosis alcoholic reports submitted per year:
Common drugs people take besides Jakafi *:
- Vicodin: 1 person, 100.00%
- Symbicort: 1 person, 100.00%
- Spiriva: 1 person, 100.00%
- Proair Hfa: 1 person, 100.00%
- Pradaxa: 1 person, 100.00%
- Golytely: 1 person, 100.00%
- Baby Aspirin: 1 person, 100.00%
Common side effects people have besides Cirrhosis alcoholic *:
- Weight Decreased: 1 person, 100.00%
- Head Injury: 1 person, 100.00%
- Abdominal Pain: 1 person, 100.00%
- Abdominal Tenderness: 1 person, 100.00%
- Adenocarcinoma (malignant tumour formed from glandular structures in epithelial tissue): 1 person, 100.00%
- Aortic Thrombosis (formation of a blood clot inside aorta): 1 person, 100.00%
- Back Pain: 1 person, 100.00%
- Breathing Difficulty: 1 person, 100.00%
- Carbohydrate Antigen 19-9 Increased: 1 person, 100.00%
- Carcinoembryonic Antigen Increased: 1 person, 100.00%
* Approximation only. Some reports may have incomplete information.
Do you take Jakafi and have Cirrhosis alcoholic?Check whether Cirrhosis alcoholic is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
How severe was Cirrhosis alcoholic and when was it recovered:
Expand to all the drugs that have ingredients of ruxolitinib phosphate:
Alternative drugs to, pros and cons of Jakafi:
- Jakafi (40,564 reports)
Common Jakafi side effects:
Browse all side effects of Jakafi:a b c d e f g h i j k l m n o p q r s t u v w x y z
Cirrhosis alcoholic treatments and more:
- Cirrhosis alcoholic (749 reports)
COVID vaccines that are related to Cirrhosis alcoholic:
- Cirrhosis alcoholic in Moderna COVID Vaccine
- Cirrhosis alcoholic in Pfizer BioNTech Covid Vaccine
- Cirrhosis alcoholic in Johnson and Johnson Covid Vaccine
All the drugs that are associated with Cirrhosis alcoholic:
- Cirrhosis alcoholic (363 drugs)
All the conditions that are associated with Cirrhosis alcoholic:
- Cirrhosis alcoholic (162 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on ruxolitinib phosphate (the active ingredients of Jakafi) and Jakafi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Clopra and Cimzia drug interaction - 10 seconds ago
- Theophylline and Conjunctival Hyperaemia - 20 seconds ago
- Alora and Hair Loss - 22 seconds ago
- Clorazepate Dipotassium and Avastin drug interaction - 27 seconds ago
- Nimotop and Depression Aggravated - 29 seconds ago
- Rashes and Herpes Simplex - 32 seconds ago
- Terconazole and Pleuritic Pain - 34 seconds ago
- Ddavp and Energy Increased - 40 seconds ago
- Luvox Cr and Extrapyramidal Disorder - 48 seconds ago
- Duragesic and Metastases To Skin - a minute ago